Biomarkers and surrogate end points in clinical trials of tuberculosis treatment

被引：5
|
作者：
Davies, Geraint Rhys
Phillips, Patrick P. J.
Nunn, Andrew J.
机构：
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
[2] MRC, Clin Trials Unit, London, England
来源：
JOURNAL OF INFECTIOUS DISEASES | 2007年 / 196卷 / 04期
关键词：
D O I：
10.1086/519744
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
下载
收藏
页码：648 / 649
页数：2
相关论文
共 50 条
  • [21] SURROGATE END-POINTS IN TRIALS OF ANTIHYPERTENSION
    BLACK, HR
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 176 - 176
  • [22] Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges
    Heinonen, Therese M.
    Aamer, Maira
    Marshall, Cameron
    Black, Donald M.
    Tardif, Jean-Claude
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (08) : 989 - 994
  • [23] INCOMPLETE MULTIRESPONSE DESIGNS AND SURROGATE END-POINTS IN CLINICAL-TRIALS
    SEN, PK
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1994, 42 (1-2) : 161 - 186
  • [24] Some statistical issues in the design of cancer clinical trials with surrogate end points
    Piantadosi, S
    ARCHIVES OF NEUROLOGY, 2000, 57 (08) : 1233 - 1233
  • [25] Blood in the stomach as a surrogate for clinical end points in GI bleeding trials.
    Hawkey, GM
    Stack, WA
    Cole, AT
    Long, RG
    Logan, RFA
    Hawkey, CJ
    GASTROENTEROLOGY, 1998, 114 (04) : A146 - A146
  • [26] Biomarkers and surrogate endpoints in clinical trials
    Fleming, Thomas R.
    Powers, John H.
    STATISTICS IN MEDICINE, 2012, 31 (25) : 2973 - 2984
  • [27] CLINICAL SURROGATE END-POINTS
    Palmeri, Sergio
    EJC SUPPLEMENTS, 2007, 5 (09): : 44 - 45
  • [28] Biomarkers and surrogate end points—the challenge of statistical validation
    Marc Buyse
    Daniel J. Sargent
    Axel Grothey
    Alastair Matheson
    Aimery de Gramont
    Nature Reviews Clinical Oncology, 2010, 7 : 309 - 317
  • [29] Research priorities in biomarkers and surrogate end-points
    Aronson, Jeffrey K.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (06) : 900 - 907
  • [30] Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency
    Maeda, H.
    Kurokawa, T.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 211 - 216
12345